Kleiner Device Labs Awarded Patent for KG®2 Surge® flow-thru interbody system

Kleiner Device Labs today announced that it was recently awarded a U.S. patent for its new KG®2 Surge® flow-thru interbody system.  This adds to the company's growing global portfolio of 35 issued patents and other intellectual property for spinal surgical technology developed by the company. 

Founder and CEO Jeff Kleiner, MD, said, "We set out from the beginning to create answers for surgeons to maximize spinal fusion bone graft delivery and solve many of the most frustrating parts of spinal fusion procedures that negatively impact both the patient and the surgeon.  Tabulating the results of our recently completed first 50 cases, we found that it took surgeons an average of only 8 minutes to trial, implant, graft and release the lumbar interbody device with the KG2 Surge system, and that both the mean and median volume of graft delivered was 10ml."

"The technology that we developed with the KG2 Surge system simplifies the post-insertion delivery of a wide range of graft materials through the interbody and into the surrounding disc space," added CTO Alan Burkholder. "Surgeons have successfully delivered milled local autograft, cortical cancellous chips, long-fiber allografts, and DBM putties.

"The simplified delivery is accomplished by marrying a rectangular inserter tube with a 3-D printed titanium interbody with a large matching opening and a bifurcated ramp that distributes the graft bilaterally. That enables filling both the cage and surrounding disc space."

The new KG2 Surge flow-thru interbody system was developed with the objectives of maximizing bone graft delivery to the prepared intervertebral disc space, and streamlining implant placement, positioning, and integration in the graft matrix. 

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!